Kim SH, Abbasi F, Nachmanoff C, et al. - In this randomized controlled trial, researchers desired to know how circulating glucagon‐like peptide‐1 (GLP‐1) concentrations during liraglutide treatment relate to its therapeutic actions on glucose and weight and to investigate the impacts of liraglutide on other proglucagon‐derived peptides (PGDPs), including endogenous GLP‐1, glucagon‐like peptide‐2, glucagon, oxyntomodulin, glicentin and major proglucagon fragment, which also regulate metabolic and weight control. Adults with prediabetes who were overweight/obese (BMI 27‐40 kg/m²) were randomized to liraglutide (1.8 mg/day) vs placebo for 14 weeks. Findings suggested that circulating GLP‐1A concentrations, representing liraglutide levels, anticipate an improvement in weight, insulin action and secretion in a linear manner. Importantly, liraglutide often downregulates other PGDPs, which can offer additional metabolic and weight loss benefits in the future by normalization of levels.